TRAIL与kallistatin联合表达载体的构建及抗肿瘤活性分析

为研究肿瘤坏死因子相关凋亡诱导配体(TRAIL)与组织激肽释放酶结合蛋白(kallistatin)联合用药的抗肿瘤作用,构建TRAIL与kallistatin双表达的重组质粒pAM-CAG-Kal-IRES-TRAIL,将重组质粒转染A549,LO-2,NCI-H446和Hela细胞,考察其抗肿瘤活性.实验结果表明:构建的双表达载体能同时表达TRAIL与kallistatin,且均能分泌至培养基中;TRAIL与kallistatin联合表达对肿瘤细胞活力的抑制作用明显增强,诱导肿瘤凋亡的作用也明显增强,说明联合表达TRAIL与kallistatin能够增强抗肿瘤活性.

Construction of TRAIL and Kallistatin Combined Expression Vector and Its Antitumor Activity Analysis

In order to study the anti-tumor effect of tumor necrosis factor-related apoptosis-inducing ligand(TRAIL)combined with kallistatin, a dual-expression of TRAIL and kallistatin recombinant plasmid pAM-CAG-Kal-IRES-TRAIL was constructed and then transfected into A549, LO-2, NCI-H446 and Hela cells with liposome to investigate the anti-tumor activity of the dual expression vector. The experimental results show that the constructed dual expression vector can express TRAIL and kallistatin simultaneously, and both of these proteins can be secreted into the culture medium; the combination of TRAIL and kallistatin expression significantly enhances the inhibition of tumor cells viability and induces apoptosis of tumor cells, which indicates that the combined expression of TRAIL and kallistatin can enhance anti-tumor activity.